Synbio International, Inc. (OTC: SYIN) has announced a strategic licensing, manufacturing, supply, and revenue sharing agreement with MD PHD Wellness, Inc., securing exclusive rights to commercialize MD PHD Wellness' proprietary nutraceutical formulations in the United States and Canada. The agreement marks a significant step for Synbio as it seeks to generate near-term revenue through commercial wellness products while continuing to develop its AI-driven mental health technologies.
The partnership covers MD PHD Wellness' flagship anti-anxiety nutraceutical formulation, which will be marketed under Synbio's Healing Force™ brand. The agreement also establishes a framework for evaluating and commercializing additional proprietary wellness products, providing Synbio with a long-term product pipeline without the time and cost burden of in-house development. This accelerates the company's path to revenue generation, a key objective for the firm.
Under the terms, MD PHD Wellness will handle product development, manufacturing, quality assurance, and supply chain management, while Synbio will focus on branding, marketing, sales, and distribution. Profits from product sales will be shared after recovery of approved manufacturing and commercialization costs. This structure allows Synbio to leverage MD PHD's expertise while concentrating on building its brand and market presence.
“This agreement represents a transformational milestone for Synbio,” said Claudio Solitario, CEO of Synbio International. “Rather than building a nutraceutical business product by product, we have established a strategic partnership that combines MD PHD’s product development and manufacturing expertise with Synbio’s commercialization capabilities. It gives Synbio immediate access to proprietary products capable of generating near-term commercial revenue while establishing a framework to expand our wellness portfolio over time, allowing management to focus on creating the greatest shareholder value - building brands, generating sales and expanding market presence.”
Solitario added, “We believe this partnership creates an efficient and scalable business model. As the global nutraceutical market continues its rapid expansion, Synbio is now positioned to participate through a growing portfolio of scientifically developed products while simultaneously advancing our longer-term AI-driven healthcare technologies.”
The scientific leadership behind MD PHD Wellness includes Dr. Robert Lawrence, a physician and scientist with two Ph.D.s in Nuclear Physics and Biomedical Engineering, and Dr. David Anderson, an experienced physician and researcher who has been recognized in Marquis Who’s Who. Their expertise in nutraceutical development and scientific validation adds credibility to the products Synbio will market.
This agreement is part of Synbio's broader strategy to build a diversified healthcare company, pairing near-term revenue from wellness products with longer-term value from its AI-driven mental health technologies. The company believes this dual-track approach provides multiple avenues for growth while establishing recurring commercial revenue to support continued innovation. As this partnership unfolds, Synbio is positioned to make its mark in the rapidly growing nutraceutical market, capitalizing on the increasing consumer demand for science-based health solutions.
